Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer.
Dually targeting the epigenetic proteins lysine specific demethylase 1 (LSD1) and histone deacetylases (HDACs) that play a key role in cancer cells by modulating gene repressor complexes including CoREST will have a profound effect in inhibiting tumour growth. Here, we evaluated JBI-097 a dual LSD1/...
Main Authors: | Chandru Gajendran, Subramanyam Janardhan Tantry, Naveen Sadhu M, Zainuddin Mohammed, Purushottam Dewang, Mahanandeesha Hallur, Sreekala Nair, Krishnakumar Vaithilingam, Basavaprabhu Nagayya, Sridharan Rajagopal, Dhanalakshmi Sivanandhan |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0279063 |
Similar Items
-
Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4
by: Chandru Gajendran, et al.
Published: (2023-02-01) -
Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex
by: Yun Song, et al.
Published: (2020-02-01) -
Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG
by: Anastas, JN, et al.
Published: (2019) -
Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells
by: Ipek Bulut, et al.
Published: (2022-12-01) -
Novel Inhibitors of Nicotinamide-<i>N</i>-Methyltransferase for the Treatment of Metabolic Disorders
by: Aimo Kannt, et al.
Published: (2021-02-01)